CA2089621A1 - Formules contenant de l'acide hyaluronique - Google Patents

Formules contenant de l'acide hyaluronique

Info

Publication number: CA2089621A1
Authority: CA; Canada
Prior art keywords: composition; hyaluronic acid; skin; drug; weight
Prior art date: 1993-02-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2089621

Other languages

English (en)

Inventor

Rudolf Edgar Falk

Samuel Simon Asculai

Ehud S. Klein

David W. Harper

David Hochman

Don Purschke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jagotec AG

Original Assignee

NORPHARMCO Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-16

Filing date

1993-02-16

Publication date

1994-08-17

1993-02-16 Application filed by NORPHARMCO Inc filed Critical NORPHARMCO Inc

1993-02-16 Priority to CA 2089621 priority Critical patent/CA2089621A1/fr

1994-08-17 Publication of CA2089621A1 publication Critical patent/CA2089621A1/fr

Status Abandoned legal-status Critical Current

Links

229920002674 hyaluronan Polymers 0.000 title claims abstract description 288
229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 287
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 286
239000000203 mixture Substances 0.000 title claims description 271
238000009472 formulation Methods 0.000 title description 83
210000003491 skin Anatomy 0.000 claims abstract description 198
239000003814 drug Substances 0.000 claims abstract description 154
210000001519 tissue Anatomy 0.000 claims abstract description 137
229940079593 drug Drugs 0.000 claims abstract description 120
150000003839 salts Chemical class 0.000 claims abstract description 76
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 74
201000010099 disease Diseases 0.000 claims abstract description 73
231100000252 nontoxic Toxicity 0.000 claims abstract description 71
230000003000 nontoxic effect Effects 0.000 claims abstract description 71
210000002615 epidermis Anatomy 0.000 claims abstract description 53
230000000699 topical effect Effects 0.000 claims abstract description 49
239000012634 fragment Substances 0.000 claims abstract description 47
150000002148 esters Chemical class 0.000 claims abstract description 38
230000002035 prolonged effect Effects 0.000 claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
230000009885 systemic effect Effects 0.000 claims abstract description 13
229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 10
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 92
206010028980 Neoplasm Diseases 0.000 claims description 82
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 80
230000003902 lesion Effects 0.000 claims description 69
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 64
230000032258 transport Effects 0.000 claims description 60
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 59
238000000034 method Methods 0.000 claims description 57
238000011282 treatment Methods 0.000 claims description 51
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
229920002385 Sodium hyaluronate Polymers 0.000 claims description 48
229940010747 sodium hyaluronate Drugs 0.000 claims description 48
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 46
208000014674 injury Diseases 0.000 claims description 46
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
206010004146 Basal cell carcinoma Diseases 0.000 claims description 44
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 43
150000003180 prostaglandins Chemical class 0.000 claims description 43
230000007170 pathology Effects 0.000 claims description 42
230000008733 trauma Effects 0.000 claims description 42
230000015572 biosynthetic process Effects 0.000 claims description 41
229960001259 diclofenac Drugs 0.000 claims description 41
238000003786 synthesis reaction Methods 0.000 claims description 38
241000701806 Human papillomavirus Species 0.000 claims description 33
210000004027 cell Anatomy 0.000 claims description 33
201000004681 Psoriasis Diseases 0.000 claims description 32
239000008223 sterile water Substances 0.000 claims description 30
235000011187 glycerol Nutrition 0.000 claims description 24
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 23
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 22
229960001193 diclofenac sodium Drugs 0.000 claims description 22
235000019445 benzyl alcohol Nutrition 0.000 claims description 21
229960000905 indomethacin Drugs 0.000 claims description 21
229960001680 ibuprofen Drugs 0.000 claims description 20
210000004324 lymphatic system Anatomy 0.000 claims description 20
208000009621 actinic keratosis Diseases 0.000 claims description 17
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 16
206010059313 Anogenital warts Diseases 0.000 claims description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 13
239000006071 cream Substances 0.000 claims description 13
210000004185 liver Anatomy 0.000 claims description 13
229960002009 naproxen Drugs 0.000 claims description 13
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 13
229960002702 piroxicam Drugs 0.000 claims description 13
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 12
239000008280 blood Substances 0.000 claims description 12
229960004752 ketorolac Drugs 0.000 claims description 12
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 12
239000003755 preservative agent Substances 0.000 claims description 12
229940124597 therapeutic agent Drugs 0.000 claims description 12
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
206010008342 Cervix carcinoma Diseases 0.000 claims description 11
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
210000000481 breast Anatomy 0.000 claims description 11
201000010881 cervical cancer Diseases 0.000 claims description 11
230000036210 malignancy Effects 0.000 claims description 11
229960003194 meglumine Drugs 0.000 claims description 11
230000002335 preservative effect Effects 0.000 claims description 11
208000003643 Callosities Diseases 0.000 claims description 10
208000000907 Condylomata Acuminata Diseases 0.000 claims description 10
206010020649 Hyperkeratosis Diseases 0.000 claims description 10
206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 10
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 10
235000002017 Zea mays subsp mays Nutrition 0.000 claims description 10
208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 10
201000004201 anogenital venereal wart Diseases 0.000 claims description 10
210000003679 cervix uteri Anatomy 0.000 claims description 10
235000005822 corn Nutrition 0.000 claims description 10
210000004904 fingernail bed Anatomy 0.000 claims description 10
230000002538 fungal effect Effects 0.000 claims description 10
208000037819 metastatic cancer Diseases 0.000 claims description 10
208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 10
208000021039 metastatic melanoma Diseases 0.000 claims description 10
230000000306 recurrent effect Effects 0.000 claims description 10
201000004384 Alopecia Diseases 0.000 claims description 9
230000003676 hair loss Effects 0.000 claims description 9
208000024963 hair loss Diseases 0.000 claims description 9
239000012071 phase Substances 0.000 claims description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 8
229960000588 flunixin Drugs 0.000 claims description 8
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 8
239000011734 sodium Substances 0.000 claims description 8
229910052708 sodium Inorganic materials 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
239000002246 antineoplastic agent Substances 0.000 claims description 7
-1 acetylsalicylic acid, propionic acid derivatives Chemical class 0.000 claims description 6
229940041181 antineoplastic drug Drugs 0.000 claims description 6
230000000717 retained effect Effects 0.000 claims description 6
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 claims description 5
239000008346 aqueous phase Substances 0.000 claims description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
238000009825 accumulation Methods 0.000 claims description 3
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
150000005599 propionic acid derivatives Chemical class 0.000 claims description 2
230000003381 solubilizing effect Effects 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
241000209149 Zea Species 0.000 claims 2
238000003756 stirring Methods 0.000 description 60
208000002193 Pain Diseases 0.000 description 59
230000036407 pain Effects 0.000 description 56
239000000499 gel Substances 0.000 description 52
230000000694 effects Effects 0.000 description 41
230000001684 chronic effect Effects 0.000 description 19
210000002540 macrophage Anatomy 0.000 description 19
230000004044 response Effects 0.000 description 19
238000001356 surgical procedure Methods 0.000 description 14
239000007788 liquid Substances 0.000 description 13
229910001220 stainless steel Inorganic materials 0.000 description 13
239000010935 stainless steel Substances 0.000 description 13
210000003127 knee Anatomy 0.000 description 12
210000005036 nerve Anatomy 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
159000000000 sodium salts Chemical class 0.000 description 12
239000000126 substance Substances 0.000 description 12
201000011510 cancer Diseases 0.000 description 11
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
210000004207 dermis Anatomy 0.000 description 10
230000000202 analgesic effect Effects 0.000 description 9
KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 9
210000002683 foot Anatomy 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
240000008042 Zea mays Species 0.000 description 8
235000019441 ethanol Nutrition 0.000 description 8
210000003128 head Anatomy 0.000 description 8
206010034464 Periarthritis Diseases 0.000 description 7
230000001613 neoplastic effect Effects 0.000 description 7
IUQJDHJVPLLKFL-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetate;dimethylazanium Chemical compound CNC.OC(=O)COC1=CC=C(Cl)C=C1Cl IUQJDHJVPLLKFL-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000012530 fluid Substances 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000008961 swelling Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
208000000491 Tendinopathy Diseases 0.000 description 5
206010043255 Tendonitis Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
230000003110 anti-inflammatory effect Effects 0.000 description 5
210000000270 basal cell Anatomy 0.000 description 5
230000036765 blood level Effects 0.000 description 5
239000003246 corticosteroid Substances 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
210000002414 leg Anatomy 0.000 description 5
201000004415 tendinitis Diseases 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
208000008035 Back Pain Diseases 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
208000007882 Gastritis Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
201000002481 Myositis Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
210000000981 epithelium Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
230000035515 penetration Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000003637 steroidlike Effects 0.000 description 4
210000000434 stratum corneum Anatomy 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000008685 targeting Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
206010063045 Effusion Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010029240 Neuritis Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
239000000061 acid fraction Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
210000003423 ankle Anatomy 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
229940083741 banamine Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000001061 forehead Anatomy 0.000 description 3
230000003779 hair growth Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
201000009985 neuronitis Diseases 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000000902 placebo Substances 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
241001274613 Corvus frugilegus Species 0.000 description 2
239000004593 Epoxy Substances 0.000 description 2
APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
201000001531 bladder carcinoma Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229960003240 floctafenine Drugs 0.000 description 2
229960000469 flunixin meglumine Drugs 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
229940089982 healon Drugs 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000008629 immune suppression Effects 0.000 description 2
230000037451 immune surveillance Effects 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
210000005067 joint tissue Anatomy 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229960003632 minoxidil Drugs 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
230000008533 pain sensitivity Effects 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
208000010570 urinary bladder carcinoma Diseases 0.000 description 2
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
102100030762 Apolipoprotein L1 Human genes 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
101100237637 Bos taurus APOL gene Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000399988 Carinoma Species 0.000 description 1
241000561734 Celosia cristata Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
206010013886 Dysaesthesia Diseases 0.000 description 1
229940019097 EMLA Drugs 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
206010016936 Folliculitis Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
206010023509 Kyphosis Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
KSQXVLVXUFHGJQ-UHFFFAOYSA-M Sodium ortho-phenylphenate Chemical compound [Na+].[O-]C1=CC=CC=C1C1=CC=CC=C1 KSQXVLVXUFHGJQ-UHFFFAOYSA-M 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
206010042135 Stomatitis necrotising Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000002240 Tennis Elbow Diseases 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000011366 aggressive therapy Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003377 anti-microbal effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
230000002965 anti-thrombogenic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
244000309466 calf Species 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000001520 comb Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000005574 cross-species transmission Effects 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
229940075911 depen Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229960005466 diclofenac diethylammonium Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000009429 distress Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000002320 enamel (paints) Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000003659 hair regrowth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
229940014041 hyaluronate Drugs 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
208000030175 lameness Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
210000001872 metatarsal bone Anatomy 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
150000002772 monosaccharides Chemical group 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
201000008585 noma Diseases 0.000 description 1
101150024399 nosL gene Proteins 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
231100000435 percutaneous penetration Toxicity 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
239000002089 prostaglandin antagonist Substances 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
230000036555 skin type Effects 0.000 description 1
229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
HLCHESOMJVGDSJ-UHFFFAOYSA-N thiq Chemical compound C1=CC(Cl)=CC=C1CC(C(=O)N1CCC(CN2N=CN=C2)(CC1)C1CCCCC1)NC(=O)C1NCC2=CC=CC=C2C1 HLCHESOMJVGDSJ-UHFFFAOYSA-N 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
239000008328 tiger balm Substances 0.000 description 1
229940096662 tiger balm Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
229940019127 toradol Drugs 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
229940063674 voltaren Drugs 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2089621 1993-02-16 1993-02-16 Formules contenant de l'acide hyaluronique Abandoned CA2089621A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2089621 CA2089621A1 (fr)	1993-02-16	1993-02-16	Formules contenant de l'acide hyaluronique

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2089621 CA2089621A1 (fr)	1993-02-16	1993-02-16	Formules contenant de l'acide hyaluronique

Publications (1)

Publication Number	Publication Date
CA2089621A1 true CA2089621A1 (fr)	1994-08-17

Family

ID=4151165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2089621 Abandoned CA2089621A1 (fr)	1993-02-16	1993-02-16	Formules contenant de l'acide hyaluronique

Country Status (1)

Country	Link
CA (1)	CA2089621A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000041730A1 (fr) *	1999-01-13	2000-07-20	Meditech Research Limited	Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
WO2002005852A1 (fr) *	2000-07-14	2002-01-24	Meditech Research Limited	Hyaluronan utilise comme agent cytotoxique, pre-sensibilisateur a des medicaments et chimio-sensibilisateur dans le traitement de maladies
WO2003018062A1 (fr) *	2001-08-27	2003-03-06	Meditech Research Limited	Protocoles therapeutiques ameliores
US6733753B2 (en)	1997-02-10	2004-05-11	Amgen Inc.	Composition and method for treating inflammatory diseases
AU2002325635B2 (en) *	2001-08-27	2007-04-05	Alchemia Oncology Pty Limited	Improved therapeutic protocols
US8623354B2 (en)	2005-09-07	2014-01-07	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8937052B2 (en)	2005-07-27	2015-01-20	Alchemia Oncology Pty Limited	Therapeutic protocols using hyaluronan
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer

1993
- 1993-02-16 CA CA 2089621 patent/CA2089621A1/fr not_active Abandoned

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6733753B2 (en)	1997-02-10	2004-05-11	Amgen Inc.	Composition and method for treating inflammatory diseases
WO2000041730A1 (fr) *	1999-01-13	2000-07-20	Meditech Research Limited	Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
US8287894B2 (en)	2000-07-14	2012-10-16	Alchemia Oncology Pty Limited	Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
WO2002005852A1 (fr) *	2000-07-14	2002-01-24	Meditech Research Limited	Hyaluronan utilise comme agent cytotoxique, pre-sensibilisateur a des medicaments et chimio-sensibilisateur dans le traitement de maladies
GB2368525A (en) *	2000-07-14	2002-05-08	Meditech Res Ltd	Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
GB2368525B (en) *	2000-07-14	2004-08-11	Meditech Res Ltd	Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
US8388993B2 (en)	2000-07-14	2013-03-05	Alchemia Oncology Pty Limited	Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
WO2003018062A1 (fr) *	2001-08-27	2003-03-06	Meditech Research Limited	Protocoles therapeutiques ameliores
AU2002325635C1 (en) *	2001-08-27	2008-09-25	Alchemia Oncology Pty Limited	Improved therapeutic protocols
AU2002325635B2 (en) *	2001-08-27	2007-04-05	Alchemia Oncology Pty Limited	Improved therapeutic protocols
US8937052B2 (en)	2005-07-27	2015-01-20	Alchemia Oncology Pty Limited	Therapeutic protocols using hyaluronan
US8623354B2 (en)	2005-09-07	2014-01-07	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Legal Events

Date	Code	Title	Description
1993-02-16	EEER	Examination request
2007-07-30	FZDE	Dead

Publication	Publication Date	Title
AP475A (en)	1996-03-08	Pharmaceutical formulations containing hyaluronic acid.
US5824658A (en)	1998-10-20	Topical composition containing hyaluronic acid and NSAIDS
US5914322A (en)	1999-06-22	Treatment of disease and conditions
US5977088A (en)	1999-11-02	Formulations containing hyaluronic acid
AU768058B2 (en)	2003-11-27	Topical composition containing hyaluronic acid and NSAIDs
US6147059A (en)	2000-11-14	Formulations containing hyaluronic acid
US5910489A (en)	1999-06-08	Topical composition containing hyaluronic acid and NSAIDS
US5792753A (en)	1998-08-11	Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6218373B1 (en)	2001-04-17	Formulations containing hyaluronic acid
US6114314A (en)	2000-09-05	Formulations containing hyaluronic acid
US6017900A (en)	2000-01-25	Topical composition containing hyaluronic acid and nsaids
US6103704A (en)	2000-08-15	Therapeutic methods using hyaluronic acid
US5990096A (en)	1999-11-23	Formulations containing hyaluronic acid
US6087344A (en)	2000-07-11	Formulations containing hyaluronic acid
CA2089635A1 (fr)	1994-08-17	Traitement de maladies a l'aide d'acide hyaluronique et d'anti-inflammatoires non steroidiens
BR112012015124B1 (pt)	2021-06-15	Formulação intra-articular
HK1005983B (en)	2001-08-17	Formulations containing hyaluronic acid
HK1005982B (en)	2004-03-05	Topical composition containing hyaluronic acid and nsaids